Aidea Pharma(SH:688488) Sou Hu Cai Jing·2026-01-17 18:11Core Viewpoint - Eddy Pharmaceutical (688488) has seen a significant stock price increase of 22.17% this week, closing at 21.6 yuan, with a market capitalization of 9.089 billion yuan as of January 16, 2026 [1] Trading Information Summary - Eddy Pharmaceutical reached a maximum price of 22.11 yuan on January 16, 2026, marking a near one-year high, and was listed on the Shanghai and Shenzhen Stock Exchanges' "Dragon and Tiger List" due to a price increase of 15% on January 14, 2026 [1][4] - The company’s Vice President Wang Guangrong, Yu Ke, and non-independent director Liu Yan faced regulatory measures from the Shanghai Stock Exchange for information disclosure violations [1][4] Company Announcement Summary - On January 13, 2026, Eddy Pharmaceutical's board approved a plan to issue A-shares to specific investors, aiming to raise no more than 185 million yuan for acquiring a 22.2324% stake in Nanjing Nanda Pharmaceutical and for supplementing working capital [1][4] - The company plans to acquire the minority stake in Nanjing Nanda Pharmaceutical for 130.05954 million yuan, increasing its ownership from 51.1256% to 73.3580% [2][4] - The board also decided to terminate the previous plan for a 2024 A-share issuance to specific investors [1][5] Fundraising and Financial Strategy - The total amount to be raised from the new issuance is capped at 185 million yuan, with 130 million yuan allocated for the acquisition and 55 million yuan for working capital [3][6] - The company has outlined a three-year shareholder dividend plan, committing to distribute at least 10% of the annual distributable profits in cash, with a cumulative cash dividend of no less than 30% of the average distributable profits over the past three years [2]